[et_pb_section fb_built=”1″ _builder_version=”4.5.3″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″]
We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a relevant potential target in acute myeloid leukaemia (AML).
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]